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Abstract : The capacity of indefinite self-renewal and pluripotency make human embryonic stem cells (hESCs) and
induced pluripotent stem cells (iPSCs) an attractive source for potential regenerative medicine. However, teratoma
formation is one of the major obstacles for implementing hESC-based therapeutics in a clinical setting. While this
tumorigenic capacity is known to be lost upon lineage differentiation in vitro, there is a potential risk that any residual
undifferentiated hESCs or progenitor cells may form tumors upon transplantation. To ensure the safety of hESCs in
clinical application, we thus explored the magnetic activated cell sorter (MACS) as a tool for separating undifferenti-
ated hESCs from a mixed population of hESCs and human blood mononuclear cells. Labeled with single or combi-
nations of two fluorsecein-labeled monoclonal antibodies (SSEA-3 and TRA-1-60) and subsequently stained with
anti-FITC and/or anti-PE magnetic microbeads, cells were subjected to MACS separation. While a reduction of
hESCs by depletion with a single marker was observed, there was still a significant fraction of residual hESCs in the
flow-through fraction. However, two consecutive MACS separations upon simultaneous staining of two different
hESC markers, SSEA-3 and TRA-1-60, completely depleted hESCs, as validated by flow cytometer, real-time PCR
and immunofluoresence microscopic analyses. The maximum efficacy of hESC removal using this protocol was
higher than 99.9%. No teratoma formation was observed in hESC-depleted cell injection to NOD/SCID mice. These
results indicate that the current MACS protocol with two antibodies can efficiently eliminate undifferentiated cells
from differentiated cells and greatly alleviate concerns about tumor formation by hESC-derived cellular therapeutics. 
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1. Introduction
Embryonic stem cells (ESCs) possess the ability to self-renew
indefinitely and to differentiate into almost all known tissue cell
types.1 These characteristics have attracted great attention for
their potential use in regenerative medicine. Clinical use of these
cells in tissue and cell therapy requires not only specific
pathogen-free, GMP-grade but also tumor-free terminally
differentiated cells or progenitor cells of interest. Despite
significant progress in controlling efficient differentiation of
ESCs to a specific lineage, the cellular products are at most a
mixture of differentiated and undifferentiated cells. Teratoma
forming assay has been widely utilized as evidence by the
pluripotency (i.e., developmental potential to three germ layers
in vivo) of hESCs and induced pluripotent stem cells (iPSCs).2
While differentiated cells derived from ESCs are not known to
be tumorigenic, it is of a great concern that the contaminating
undifferentiated cells residing within the population of cellular
therapeutics can give rise to teratoma in vivo upon ectopic
transplantation. Although benign, teratoma or other forms of
abnormal cellular outgrowth (tumor) pose a significant health
risk and can lead to loss of function of grafted cells and tissues.
Indeed, a recent report showed that hESCs engrafted into human
fetal tissues developed malignant tumors in SCID mice.3 The
presence of these potentially tumorigenic undifferentiated ESCs
in cellular therapeutics for regenerative medicine hampers their
clinical application. 
While murine ESCs (mESC) as well as mESC-derived
differentiated cells (insulin-producing cells, cardiomyocytes,
neurons) produced teratomas upon injection into
immunocompromised mice,2 the incidence of teratoma formation
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in immunocompromised animal models by hESC-derived
differentiated cells was relatively low compared to murine cells.3
Lee et al.4 suggested that the number of engrafted hESCs is a
critical factor for teratoma formation, showing a minimum
requirement of 1×104 ~ 1×105 hESCs for teratoma development
in the myocardium and in skeletal muscle, respectively.
However, van der Bogt et al.5 reported that subcutaneous
injection of ~100 hESCs can induce teratoma formation,
suggesting that contamination of hESC-derived therapeutic
cells with undifferentiated cells may cause tumor formation.
The discrepancies between mESCs and hESCs in terms of
teratogenic potential could be due to species-barriers
(microenvironment differences from human cells to murine
tissues) or to differences in the de novo capacity of two ESCs in
teratoma formation. Other variables including route of injection
(subcutaneous, intratesticular, intramuscular and under kidney
capsule), composite of injected cells (single cell suspension,
aggregates and/or coinjection with Matrigel) and duration, all
of which may greatly influence the outcome of tumorigenesis of the
injected cells.4,6 Since the absence of teratoma formation in hESC- or
iPSC-derived differentiated cells in immunocompromised mice may
also be due to immune rejection, these experimental models do
not guarantee their safety in human application. 
Due to these variables and uncertainties, clinical application
of hESC-derived differentiated cells would require a firm
guarantee that they are free from the risk of tumorigenesis.
Various approaches have been introduced to avoid this
problem.7 First, generation of genetically engineered ESCs can
ensure elimination of undifferentiated ESCs from a cellular
product. ESCs equipped with suicide genes under the control of
the promoter of stemness genes render undifferentiated cells
sensitive to gancyclovir.8 Alternatively, genetic modification of
hESCs with a1,3-galactosyltransferase under hTERT promoter
make the undifferentiated cells highly apoptotic to normal
human serum.9 While promising in removing undifferentiated
cells, the introduction of xenogene(s) limits their clinical
translation, as genetic manipulation raises another regulatory
concern. Second, selective induction of apoptosis of the
undifferentiated cells in the cellular mixture has been
introduced.10,11 While attractive, this approach requires further
confirmation of lack of activity to differentiated cells, as some
of these molecules may participate in vital processes of other
cell types. In addition, intermediate stage (progenitor)
therapeutic cells may be affected by the chemicals. Third,
generation of pure differentiated cells from hESCs is an ideal,
as differentiated cells lose their ability to form teratoma and
possess extremely limited differentiation capacity in vivo.
Brederlau et al. reported that the duration of in vitro differentia-
tion of hESCs to differentiated cells was inversely related to the
incidence of teratoma in rats, implying that long-term in vitro
differentiation reduces the content of undifferentiated cells
among differentiated cells.12 However, current methods of
differentiation are not able to yield differentiated cells without
contaminating undifferentiated hESCs. As a small fraction of
residual undifferentiated hESCs among the differentiated cells
can generate teratoma in clinical settings, better, more efficient
differentiation protocols for hESCs need to be further explored.
Fourth, positive selection (enrichment) of differentiated cells or
negative selection (depletion) of undifferentiated cells from
heterogeneous cellular mixtures by antibody can be employed.
Developed, explored and refined in the fields of immunology
and hematology for isolation of specific cell types by
antibody,13 these strategies may complement the afore-
mentioned strategies including efficient differentiation
protocol. Currently, three major methods for cell isolation by
monoclonal antibodies are available: (1) fluorescence-
activating cell sorters (FACS), (2) magnetic-activated cell
sorter (MACS) and (3) complement-mediated lysis. Of these,
MACS provide fast and efficient segregation of undesired cells
with great ease. Notably, if the efficiency of a single antibody is
low, it is possible that combination(s) of two or more of
antibodies can be applied for better resolution. Among the
candidates, antigens of globo-series glycolipids (SSEA-3,
SSEA-4) and keratin sulfate-related antigens (TRA-1-60 and
TRA-1-81) are known to be highly expressed in hESCs and
down-regulated upon differentiation.14 Depletion of
undifferentiated SSEA-4-positive cells ESCs prevented the
formation of teratoma in ESC-derived hematopoietic precursor
cells in allogeneic settings.15 Recently, Choo et al.16 reported
that one monoclonal antibody to specific epitope of PODXL
induces selective apoptosis to undifferentiated hESC. Still, the
drawback to these approaches is that certain markers can be
expressed in differentiated cells of specific lineage, as in the
case of SSEA-4 in neural lineage (neural precursor cells),17 thus
limiting their utilization. 
In the present study, we examined the efficiency of hESC
ablation among differentiated cells by four well-known hESC-
specific monoclonal antibodies with MACS to ensure the
safety of differentiated cellular therapeutics derived from
hESCs. To do this, hESC depletion by single and combinations
of antibodies to known hESC makers were examined. To
determine whether this strategy prevented tumor formation, we
transplanted the sorted cells to immunocompromised mice and
demonstrated that a combination of SSEA-3 and TRA-1-60
completely ablated undifferentiated hESCs among the
differentiated cells.
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2. Materials and Methods
2.1 Human Embryonic Stem Cells and Cell Culture
The work with human ESCs was approved by the Korean
Food and Drug Administration as well as the Institutional
Review Board of Yonsei University College of Medicine (IRB
No. 4-2010-0277). The human embryonic stem cell lines,
SNU-hES3 (P30–36) and CHA-hES3 (P88-93), were provided
by Seoul National University Hospital (Seoul, Korea) and CHA
Hospital (Seoul, Korea), respectively. The cells were routinely
cultured in DMEM/F12 supplemented with 20% (v/v)
Knockout Serum Replacements, penicillin (100 IU/ml) and
streptomycin (100 ug/ml), 0.1 mM nonessential amino acids (all
from Invitrogen, Carlsbad, CA, USA), 0.1 mM mercaptoethanol
(Sigma Chemical Co., St. Louis, MO, USA), and 4 ng/ml basic
FGF (Invitrogen) as previously described.18 SNU-hES3 and
CHA-hES3 cell lines were grown on the layer of mitotically
arrested STO (ATCC, Manassas, USA) feeder cells and mouse
embryonic fibroblasts (MEFs), respectively. The media were
changed daily and hESC colonies were transferred to a fresh
feeder layer every 5-7 days by mechanical passaging.18
2.2 Neural Differentiation of hESCs 
To prepare embryoid bodies (EBs), hES cell colonies were
detached from feeder cells by being incubated with 2 mg/ml of
type IV collagenase (Invitrogen) for 30 min and transferring the
colonies to Petri dishes containing normal hESC culture
medium without bFGF (EB medium). For spontaneous
differentiation, EBs were cultured for seven days with medium
change every two days. Neural precursor cells and spherical
neural masses (SNM) were prepared as described previously.19
Seven days after EB formation, EBs were cultured in neural
precursor cell (NPC) selection media (DMEM/F12 with 1× N2
supplement (Invitrogen) containing bFGF (20 ng/ml) for five
days, and the resulting NPCs were expanded for another four
days in a modified EB medium containing a 0.5% N2
supplement without serum or serum replacement. For SNM
formation, neural rosettes and neural tube-like structures that
were observed during neural expansion culture were
mechanically isolated and cultured onto bacterial culture dishes
containing the NP expansion medium. SNMs were
mechanically fragmented into 4~6 pieces and expanded for 7–
10 days for passaging. 
2.3 Preparation of Single Cell Suspension for Sorting
and Flow Cytometry
Single cell suspension of hESCs was prepared as described
previously,20 with some modifications. For detaching hESC
cells from feeder layer, ROCK inhibitor (10 µM Y-27632,
Sigma)21 or thiazovivin (0.5 µM, Stemgent, San Diego, CA,
USA)22 was added prior to enzyme treatment. Upon treatment
with 1.5 mg/ml of collagenase type IV (Warthington, NJ,
USA), clumps of hESCs were collected and further treated with
TryPLE Express (Invitrogen). Cell separation was performed
using MACS according to the manufacturer’s instruction
(Miltenyi Biotech, Auburn, CA, USA). Dissociated cells were
passed through a 70-µm cell strainer (BD Pharmingen, San
Diego, CA, USA) and stained using PE-conjugated anti-SSEA-
3, FITC-conjugated anti-SSEA-4 and FITC-conjugated anti-
TRA-1-60 or a combination of PE-conjugated anti-SSEA-3
and FITC-conjugated anti-TRA-1-60 (all from BD
Pharmingen) at 4oC in PBS/EDTA/0.1% BSA containing
100 units/ml DNase I (Sigma) for 15 min. Cells were washed in
PBS containing 5 mM EDTA, resuspended in PBS containing
5 mM EDTA and BSA and stained with either anti-PE-, anti-
FITC-microbeads or a combination of both for an additional 15
min at 4 C. After washing, stained hESCs were sorted with two
consecutive MACS columns (LS or LC column) as shown in
Fig 1. After collection, pre-stained cells and cells of positive
and negative fractions were analyzed by flow cytometer, real
time-PCR or immunofluorescence microscope for cells stained
with fluorochrome-conjugated antibodies to assess purity. 
Cell surface antigens were labeled through incubating with
fluorescein-conjugated primary antibodies for 15 min in the dark
at 4oC. The stained cells were analyzed by Cytomics™ Flow
Figure 1. Schematic of serial MACS for the depletion of undiffer-
entiated hESCs. After staining with two different antibodies to
specific surface markers, the cells were then sorted into 2 consec-
utive MACS columns (LS column) to deplete unwanted (anti-
body-bound) cells from the mixture of heterogenous cells.
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Cytometer (Beckman Coulter, Fullerton, CA, USA). Twenty
thousand events were registered per sample and cell analysis was
performed using the appropriate scatter gates to avoid cellular
debris and aggregates. Data were processed using WinMDI 2.8
software (http://facs.scripps.edu/help/html/read1ptl.htm).
Efficiency of hESC depletion was calculated using the following
equation: Efficiency (%) = 1 – (% hESC cells in the flow-through
fraction/% hESC in starting population).
2.4 Formation of Tumors in SCID Mice and Histological
Analysis
All animal procedures were approved under the guidelines of
the Health Sciences Animal Policy and Welfare Committee of
the Yonsei University College of Medicine (IACUC #2010-
0193). Single cell suspension of hESC-depleted (negative
fraction of SSEA-3 and TRA-1-60 MACS-sorting) or hESC-
enriched fraction cells were washed once in PBS, then
resuspended in PBS at 2×106 cells/ml. A 100 µl aliquot was
implanted beneath the testicular capsule of young (8-week)
female NOD/SCID mice (Orent Bio, Seoul, Korea). Teratoma
growth was determined weekly by palpation, and the mice were
sacrificed (cervical dislocation) 12 weeks after implantation.
The tissue was fixed, and sections were stained with
Hematoxylin & Eosin. Immunohistochemistry was performed
on formalin-fixed/paraffin-embedded tissues. The sections
were deparaffinized in xylene and hydrated through sequential
ethanol gradient. Antigen retrieval was carried out by heating
the sections in citrate-EDTA buffer (10 mM citric acid, 2 mM
EDTA, 0.05% Tween-20, pH 6.2) or Tris-EDTA buffer (10 mM
Trizma-base, 1 mM EDTA, 0.05% Tween-20, pH 9). The
sections were blocked for 30 minutes in 5% serum. Human
nuclear antigen (HuNu, Chemicon, Temecula, CA, USA)
staining was performed using an HRP-conjugated secondary
antibody followed by incubation with diaminobenzidine
solution (Vector Laboratories, Burlingame, CA, USA). 
2.5 Quantitative RT-PCR (qRT-PCR) Analyses
Total RNA was extracted using a Easy-Spin® total RNA
purification kit (iNtRON Biotechnology, Seoul, Korea)
according to the manufacturer’s instructions and then 1 µg of the
total RNAs were reverse transcribed with Power cDNA
synthesis kit (iNtRON). qRT-PCR was performed using SYBR
Premix Ex Taq TM (Takara Bio Inc, Shiga, Japan) and the
reaction was carried out using the My-iQ or CFX96 Real-Time
System (Bio-Rad, Hercules, USA) under the following
conditions; (step 1) 1 min at 95oC; (step 2) 40 cycles of 20 s at
95oC, 20 s at 63oC, and 20 s at 72oC; (step 3) final extension for
1 min at 72oC. The expression values (Ct values) of specific
marker genes were collected and normalized according to those
of β-actin, and then the normalized expression levels of the
markers were compared between MACS-sorted cells according
to the ∆∆Ct method.23 All of the data was confirmed by at least
three independent experiments. The primer sequences were as
follows: Oct4-F 5’-tgg gct cga gaa gga tgt g-3’’ Oct4-R 5’-gca tag
tcg ctg ctt gat cg-3’; β-actin-F 5’-gct ctt ttc cag cct tcc tt-3’; β-
actin-R 5’-ctt ctg cat cct gtc agc aa-3’. For statistical analysis,
∆∆Ct values of samples were subjected to a one-tailed t-test.
Significant differences between groups were defined as p < 0.01.
3. Results
3.1 Marker Changes During In Vitro Neural Differentia-
tion of hESCs 
Undifferentiated hESCs are typically characterized by
positive staining for pluripotent stem cell markers, such as
SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, Oct4 and Nanog. We
examined the expression profiles of the surface markers during
the differentiation of hESCs toward neural lineage cells. While
surface expression of SSEA-3 and TRA-1-60 was dramatically
down-regulated in neural precursor cells (from 98.3±5.2 to 8.3
±4.6 for SSEA-3 and from 83.7±9.1 to 1.6±1.2 for TRA-1-60,
respectively), TRA-1-81 was expressed in substantial amount
in neural precursor cells (Fig 2).
Stage specific embryonic antigen 4 (SSEA-4) was
continuously expressed on neural rosettes and spherical neural
masses (SNM), albeit at a reduced level. This result implies that
(1) ESC-derived neural progenitor and precursor cells resemble
native human embryonic brain-derived neural progenitor cells
as the latter expresses SSEA-417 and (2) SSEA-4 is not a
suitable marker for undifferentiated ESC ablation in neural
lineage cells. Thus, our data indicate that cells of SNM are
highly related to typical neural progenitor cells of the normal
human brain. 
3.2 Depletion of Undifferentiated hESCs by a Single
Marker
The data from flow cytometric analyses of key stem cell
markers suggest that these markers can be used for hESC
depletion from heterogeneous population of differentiated
cells. To do this, we examined whether each marker can deplete
significant portions of hESCs among differentiated cells by
MACS. For separation and subsequent transplantation, we
deliberately generated a mixture of hESCs and normal human
peripheral blood mononuclear cells (PBMCs) at a ratio of 1:4
~1:5. Thus, the starting cell population contained 20~25%
hESC-marker positive cells (Fig 3). PBMC cells displayed little
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positivity to these hESC makers. Since SSEA-4 was
continuously expressed on differentiated cells derived from
hESCs, we did not perform further analysis of SSEA-4. When
a monoclonal antibody to a single marker was utilized,
depletion of hESCs among flow-through (negative) fraction
was incomplete. Routinely, 3-5% of negative fractions
contained marker-positive cells (hESCs). Retention of marker-
positive cells in the MACS column were 60~80%. This is in
line with one previous report,24 in which a single antibody
yielded 4-7% contaminated hESCs on the negative fraction.
Figure 2. Flow cytometric analysis of hESCs, EBs and neural precursor cells. Representative histograms of the human ESC line (SNU-
hES3) expressing SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81. SSEA-4 and TRA-1-81 are substantially expressed on neural precursor
cells. Isotype control is shown as an open histogram.
Figure 3. Immunomagnetic selection of hESCs from a mixture of hESCs and normal human PBMCs. Prior to separation, hESCs and
normal human PBMCs were deliberately mixed with a ratio of 1:4 ~1:5. After staining with fluorochrome-conjugated antibodies against
SSEA-3, TRA-1-60 or TRA-1-81 cells and subsequently with microbead-conjugated anti-PE- or anti-FITC antibodies, cells were sub-
jected to MACS separation. Depletion of marker expressing cells in the flow-through fraction still contained substantial amounts of
undifferentiated marker-positive cells.
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3.3 Depletion of Undifferentiated hESCs by Dual
Markers
Since these pluripotency markers are not completely shared
by all hESCs, we attempted to utilize two monoclonal
antibodies to completely deplete hESCs expressing even a
single antigen. In addition, we assembled two MACS column
top to bottom to deplete further the antibody-stained cells from
the flow-through fraction of the first column (Fig 1). Upon
retrieval from the MACS column, the purity of flow-through
reached an almost 100% hESC-free cell population (Fig 4A).
Combination of SSEA-3 and TRA-1-60 antibodies yielded less
than 0.1% hESCs. Two serial MACS purifications significantly
reduced the number of eluted cells by 50%. Increases in
marker-negative cell numbers in the positive fraction were due
to high retention during the two consecutive column separation,
as compared to the single quick MACS separation for single
marker-base sorting. In addition, blood monocytes in the
PBMC served as a main contaminating cell type in the positive
fraction as they express FcR and captured monoclonal
antibodies to hESCs in a nonspecific manner, despite the
presence of a high concentration of FcR blocking reagents. 
The absence of contaminating undifferentiated hESCs
(SSEA-3- and/or TRA-1-60-positive cells) in the negative
fract ion  was  fur ther  conf i rmed by de tec t ion  of
immunofluorescent cells under microscopic observation (Fig
4B). In contrast, fluorescent cells were frequently detected on
the positive fraction. In addition, qRT-PCR further confirmed
the absence of Oct-4+ cells in the negative fraction (Fig 4C). 
3.4 Teratoma Formation
Flow-through (negative) fraction failed to generate teratoma
in NOD/SCID mice for at least 12 weeks. The viability of both
positive and negative fractions was routinely above 80%. These
data suggest that purified single cell suspensions are highly
fragile or unable to gain access to the vascular network of host
tissue to survival. Undifferentiated hESCs as aggregates
corresponding to 1×105 cells formed teratoma in NOD/SCID
mice (Fig 5), positive fractions containing single cell
suspension of hESCs failed to produce teratoma in the
immunodeficient mice after 12 weeks. We further tested
whether the transplanted hESCs remained 12 weeks after
transplantation by immunohistochemical staining of anti-
Figure 4. Complete depletion of hESCs by serial MACS with two hESC surface markers. Representative flow cytometric data of SSEA-
3 and TRA-1-60 expression in (A) the unsorted mixed population of hESCs and PBMCs, the cells retained in the column (positive frac-
tion), and the flow-through fraction are shown. The values are ratios of single positive or double positive cells to SSEA-3 or TRA-1-60.
(B) No SSEA-3+ could be detected in the “flow-through” fraction in contrast with frequent fluorescent cells in the positive fraction and
unsorted cells. Immunofluorescence of SSEA-3-stained cells (green) is shown with DAPI-stained nuclei (shown in blue). (C) qRT-PCR
of Oct4 confirmed the absence of hESCs in the “flow-through” fraction. The relative Oct4 gene expression of each cell fraction was
determined by real-time PCR. Oct4 gene expression was normalized to β-actin. *p <0.01. 
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human nuclear antigen. No hESC-derived cells were detected
in the cells of testis tissue (data not shown). Normal mouse
testis tissue sections served as an internal negative control. In
order to assess the viability of hESCs upon dual MACS column
separation, we induced the formation of an embryoid body
from cells of positive fraction. As shown in Fig 5B, typical EB
aggregates were formed, indicating that cells subjected to
MACS separation retain viability during in vitro manipulation
(i.e., cell harvesting, washing, staining, MACS separation and
elution from column). 
4. Discussion
At present, the generation of pure therapeutic cells from
hESCs remains a challenge; thus, it is essential to develop a
strategy to delete the residual undifferentiated cells with
teratogenic potential. Here, we have presented our data showing
that two consecutive MACS column separation with a
combination of two monoclonal antibodies were able to achieve
this goal. Conventional hESC markers (SSEA-3, SSEA-4,
TRA-1-60 and TRA-1-81) were examined for their efficiency of
hESC depletion by MACS. For decades, MACS has provided
the most selective approach for positive selection and negative
depletion and had been successfully applied to basic and clinical
research for purifying, ablating specific cell types of interest.
The limiting factors of MACS separation are the presence of (1)
selectable markers and (2) high affinity antibody to the markers.
From the flow cytometric data, we gathered that SSEA-3,
SSEA-4, TRA-1-60 and TRA-1-81 were good candidates for
MACS selection and applied them to our current strategy. 
While we provided evidence that a combination of ESC
markers could completely deplete undifferentiated cells, certain
ESC marker(s) may not be suitable for depleting undifferentiated
cells depending on cell lineage. For example, Shibata et al.15
demonstrated that removal of SSEA-4-positive cells in
cynomolgus ESC-derived hematopoietic precursors prevented
the formation of teratoma in allogeneic transplantation. However,
this marker cannot be used in neural cell lineages as we found
that ESC-derived neural precursor cells commonly expressed
this marker, albeit at a lower level than ESC. This is in
accordance with a previous report17 showing that human brain
neural progenitor cells expressed SSEA-4. 
Figure 5. Histological analysis of testis tissue upon intratesticular transplantation reveals no teratoma formation. (A) Photomicrographs
of NOD/SCID mouse testis tissue obtained 12 weeks postimplantation of 2×105 cells of hESC-depleted (negative fraction) or hESC-
enriched (positive) fraction into the testicular capsule of the host mice. None of the transplanted testes showed evidence of tumor or ter-
atoma formation on histological evaluation upon H&E staining. (B) Formation of teratomas after transplanted hESC aggregates into the
testes of NOD/SCID mice. Histological analysis of the teratoma reveal the presence of mesodermal and endodermal tissues defined by
Alician blue stained cartilage (left) and gut epithelium-like structure (right), respectively. Magnification ×100. (C) EB aggregates were
formed from SSEA-3+TRA1-60+ fraction of MACS isolation. Positive fraction cells from MACS column retained viability during in
vitro manipulation.
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The two-consecutive MACS strategy provided that SSEA-3+
and/or TRA1-60+ cells of flow-through fraction contained less
than 0.1% of cells from a mixture of 10-25% hESCs with
differentiated cells (PBMC). Since the resolution of flow
cytometric phenotyping routinely exceeds the level of 0.01%,
we further examined the content of hESCs among the negative
fraction by immunofluorescence microscope. Of more than
10,000 cells examined, no fluorescent cell (antibody-stained
cell) was detected implying that the contamination did not
exceed 0.01% of the total cells. In addition, no signal was
detected by RT-PCR of the negative fraction, implying that this
approach can y ie ld  a lmost  complete  ablat ion  of
undifferentiated hESCs among negatively selected cells. In
addition, we failed to observe any teratoma formation in hESC-
depleted (negative) fraction as well as in hESC-positive
fraction for at least 12 weeks. Unlike in other reports6,25 with
hESC aggregates (equivalent to 106 hESCs), we injected single
cell suspensions of 2×105 cells (i.e., containing less than 5×104
hESCs in the positive fraction of MACS separation) and
observed no teratoma formation in the testis by the positive
fraction. Typically, the rate of teratoma formation in the testis
has been found to be 94% when 1×106 undifferentiated cells
were injected.26 The reason for this could be due to (1) the lack
of tumorigenic potential in small numbers of hESCs, (2)
suboptimal number of hESCs or (3) poor viability of single cell
suspension after MACS as compared to the aggregate form
normally used. This is in line with a previous report by Hentze
et al.,6 which stated that there was a linear correlative
relationship between the number of cells and the time required
to form teratoma by single cell-adapted hESC lines at passage
below 30. Low efficiency of teratoma formation may also be
due to the subculture method of hESC maintenance.
Collagenase-passaged hESCs failed to generate teratoma when
single cell suspension was prepared using trypsin digestion,
unlike efficient teratoma formation by trypsin-adapted
hESCs.27 Given that teratoma formation must be prevented in
clinical cases, this result with single cell suspension containing
hESCs provides promise for a cell therapy strategy.
A recent publication by Schriebl et al.28 with a mESC model
proposed that MACS technology is theoretically insufficient to
achieve purification of undifferentiated cell-free cellular
therapeutics derived from ESCs. By their mathematical
estimation, more than 30 steps of repetitive MACS separation
is required to achieve less than 10-1 cells among 109 cells for
therapy, which may not be feasible for viability and quantity of
outcome. This model, however, reflected the safety issue too
strictly by limiting contaminating cells to 0.0000001% of the
total. Based on the differences in efficiency of teratoma
formation between murine and human hESCs, the minimum
required number of hESCs for teratoma formation has not been
evaluated thoroughly and may not be in this range, but at least
to the 2-4 order higher than this in reality. In addition, other
variables, including the viability of hESCs in vivo as a single
cell suspension, survival, immunological recognition and
eventual formation of tumors in the local microenvironment
will further increase the order by a factor of 2-3. Considering
these parameters, 104~105 cells in 109 cells (i.e., 0.001~0.01%)
would serve as a safe margin for their clinical application. In
line with this, Shibata et al.15 reported that the purging of
SSEA-4-positive cells from cynomolgus ESC-derived
hematopoietic progenitor cells prevented the formation of
teratoma upon transplantation into the allogeneic monkey
model. While flow cytometric depletion of hESCs would yield
a purer population with little or no contaminating cells, only a
few studies have succeeded with this technique due to its slow
sorting speed, which affects the viability of sorted cells
significantly.15,29,30 Further refining of MACS separation by
high avidity antibodies and protocols, on the other hand, may
provide means to fast and efficient depletion or purification
with greater survival.
In conclusion, our results demonstrated that two-column
MACS separation is efficient in complete depletion of hESCs
among a heterogeneous cell population. As the overall process
of staining and separation do not exceed one hour, the viability
of both positive and negative was acceptable as determined by
trypan blue and EB forming assay. Thus, MACS strategy can
yield a highly pure undifferentiated hESC-free, viable cell
preparation suitable for their clinical application. Multi-step
MACS with antibodies against two or more markers with high
specificity and avidity may offer a better resolution for
conferring cellular therapeutics with no tumorigenic potential.
Utilization of other strategies for selective ablation and/or
apoptosis by chemical or cytotoxic antibody may further
enhance the efficiency of specific cell isolation and/or
depletion. 
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